RxDoctor Payments Data

Gary Clay, MD

Family Medicine · Miami, FLNPI 1548705239

Payments from drug & device makers

$406in general payments, 2019–2025

Across 18 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$112
  • Neurocrine Biosciences, Inc.$102
  • Viiv Healthcare Company$88
  • Novartis$45
  • Merck$33
  • GSK$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$235,748
Medicare patients
326
Services billed
2,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban319$94,979
TrulicityDulaglutide68$47,864
XareltoRivaroxaban59$16,485
JanuviaSitagliptin Phosphate57$16,034
ProcritEpoetin Alfa12$12,580
Nystatin202$9,693
JardianceEmpagliflozin29$9,261
Atorvastatin Calcium402$6,816
FarxigaDapagliflozin Propanediol19$6,055
Sevelamer Carbonate11$6,000
RetacritEpoetin Alfa-Epbx13$5,629
Gabapentin283$5,606
Midodrine Hcl83$5,552
Fiasp FlextouchInsulin Aspart (Niacinamide)23$5,170
Levetiracetam137$4,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$33$16,03457 claims
NovartisEntresto$45$4,09011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →